BillionToOne, Inc. (BLLN)
NASDAQ: BLLN · Real-Time Price · USD
104.43
+0.16 (0.15%)
Sep 16, 2026, 3:00 PM EDT - Market open
BillionToOne Revenue
BillionToOne had revenue of $109.45M in the quarter ending June 30, 2026, with 64.40% growth. This brings the company's revenue in the last twelve months to $397.41M, up 90.12% year-over-year. In the year 2025, BillionToOne had annual revenue of $305.11M with 99.97% growth.
Revenue (ttm)
$397.41M
Revenue Growth
+90.12%
P/S Ratio
12.49
Revenue / Employee
$557,380
Employees
713
Market Cap
4.93B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 305.11M | 152.53M | 99.97% |
| Dec 31, 2024 | 152.58M | 80.85M | 112.72% |
| Dec 31, 2023 | 71.73M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
BLLN News
- 7 days ago - BillionToOne Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 13 days ago - BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference - PRNewsWire
- 14 days ago - BillionToOne initiated with a Buy at Canaccord - TheFly
- 15 days ago - BillionToOne announces the launch of Northstar Origin - TheFly
- 15 days ago - BillionToOne launches Northstar Origin, a new liquid biopsy test - TheFly
- 15 days ago - BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin - PRNewsWire
- 4 weeks ago - BillionToOne announces publication of study on cfDNA fetal risk assessment - TheFly
- 4 weeks ago - Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions - PRNewsWire